...it to the clinic but been discontinued, including a recombinant fusion protein from now defunct VaxInnate Corp....

...Euronext:SAN; NYSE:SNY, Paris, France) in up to 450 healthy adults. The trial is funded by VaxInnate’s...
...Advanced Research and Development Authority (BARDA) (see BioCentury, March 7, 2011 & March 9, 2015). VaxInnate Corp....

...chief information officer from VP of pharmaceutical operations and corporate information technology. Infectious disease company VaxInnate Corp....

...binds a conserved region on hemagglutinin, in Phase II testing to treat influenza A virus. VaxInnate Corp....

...The contract extension will provide the remaining $53 million in funding through February 2016. VaxInnate...
...2Q15; a Phase I and Phase II trial of VAX161C; and to prepare commercial formulations. VaxInnate...
...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....

...12, 20, 28 or 36 µg VAX2012Q in up to 200 healthy volunteers ages 65-75. VaxInnate Corp....

...tolerated with mild to moderate arm pain reported as the most common adverse event. Additionally, VaxInnate...
...mean seroprotection rates of >90% for each of the 4 vaccine components at day 21. VaxInnate Corp....

...Inc. (NASDAQ:NVAX); Johnson & Johnson (NYSE:JNJ) Phase I/II Flagellin TLR5 ligand VAX102, an influenza vaccine VaxInnate Corp....

...Lead indication Status Immune Design Corp. (NASDAQ:IMDZ) G100 TLR4 Merkel cell carcinoma (MCC) Ph I VaxInnate Corp....
...BioLabs Inc. (NASDAQ:CLBI) Entolimod (CBLB502) TLR5 Acute radiation syndrome (ARS); solid tumors Ph I (A) VaxInnate Corp....

...intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's...
...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....